Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (121-130 of 213) with videos related to

Pageof 22
Sort By:
Neoplasia (New York, N.Y.)|December 18, 2007
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the boneKuei C Lee, Deborah A Bradley, Maha Hussain, et al.
Cell Death & Disease|October 24, 2019
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cellsVinay Sagar, Rajita Vatapalli, Barbara Lysy, et al.
European Urology Focus|May 16, 2025
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysisMarcin Miszczyk, Tamás Fazekas, Paweł Rajwa, et al.
The Journal of Urology|October 22, 2008
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladderDavid C Smith, Niklas J Mackler, Rodney L Dunn, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of the National Cancer Institute|February 26, 2014
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421Primo N Lara, Benjamin Ely, David I Quinn, et al.
Advances in Radiation Oncology|August 12, 2017
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomyWilliam C Jackson, Felix Y Feng, Stephanie Daignault, et al.
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
The Journal of Clinical Investigation|June 22, 2023
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growthGalina Gritsina, Ka-Wing Fong, Xiaodong Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Pageof 22

Showing results (121-130 of 213) with videos related to

Sort By:
Pageof 22
Neoplasia (New York, N.Y.)|December 18, 2007
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the boneKuei C Lee, Deborah A Bradley, Maha Hussain, et al.
Cell Death & Disease|October 24, 2019
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cellsVinay Sagar, Rajita Vatapalli, Barbara Lysy, et al.
European Urology Focus|May 16, 2025
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysisMarcin Miszczyk, Tamás Fazekas, Paweł Rajwa, et al.
The Journal of Urology|October 22, 2008
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladderDavid C Smith, Niklas J Mackler, Rodney L Dunn, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of the National Cancer Institute|February 26, 2014
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421Primo N Lara, Benjamin Ely, David I Quinn, et al.
Advances in Radiation Oncology|August 12, 2017
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomyWilliam C Jackson, Felix Y Feng, Stephanie Daignault, et al.
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
The Journal of Clinical Investigation|June 22, 2023
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growthGalina Gritsina, Ka-Wing Fong, Xiaodong Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
Pageof 22